Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AuraSTOP
- Development stage
- Unknown
- Lead developer
- Aesculapius
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AuraSTOP is a dietary supplement (nutraceutical) developed and marketed by Aesculapius Farmaceutici, primarily indicated for the prevention and management of migraines, including those associated with aura. It is a fixed-dose combination of three active components: *Tanacetum parthenium* (Feverfew) extract, *Griffonia simplicifolia* extract, and Magnesium. *Tanacetum parthenium* is standardized for parthenolide, which acts as an anti-inflammatory agent by inhibiting NF-kappaB and reducing the release of serotonin and prostaglandins from platelets. *Griffonia simplicifolia* is a natural source of 5-hydroxytryptophan (5-HTP), a direct precursor to serotonin, which helps modulate pain thresholds and mood. Magnesium serves as an essential mineral that regulates neuronal excitability, often by acting as a physiological antagonist at the NMDA receptor. Together, these ingredients aim to reduce the frequency and intensity of migraine attacks and counteract localized tension.
- Brand names
- AuraSTOP
02
Targets
Glycine co-agonist site on the Glutamate receptor ionotropic NMDA type subunit 1NMDAR (Glutamate receptor ionotropic, NMDA)TRPA1 (Transient receptor potential cation channel subfamily A member 1)
Beyond the preview
Go deeper on AuraSTOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AuraSTOP.